Table 1.
Drugs targeting candidate epigenes from modules 4, 6, 8, and 10–12.
| Target protein | Drug name | Module | Function |
|---|---|---|---|
| TOP2A | Genistein, fluorouracil, intoplicine, enoxacin, sparfloxacin, amrubicin, etoposide, epirubicin, ciprofloxacin, myricetin, mitoxantrone, trovafloxacin, RTA 744, daunorubicin, norfloxacin, finafloxacin, dexrazoxane, 13-deoxydoxorubicin, idarubicin, lomefloxacin, lucanthone, pefloxacin, valrubicin, amsacrine, levofloxacin, doxorubicin, declopramide, annamycin, banoxantrone, ZEN-012, podofilox, aldoxorubicin, teniposide, moxifloxacin, SP1049C, amonafide, dactinomycin, fleroxacin, becatecarin, ofloxacin, and elsamitrucin | Module 8 | Epifactor (chromatin remodeling) |
| BRD4 | Fedratinib, panobinostat, romidepsin, birabresib, alprazolam, vorinostat, volasertib, alobresib, belinostat, and apabetalone | Module 6 | Epifactor (histone modification read) |
| EP300 | Curcumin | Module 6 | Epifactor (histone modification write) |
| DNMT1 | S-adenosyl-L-homocysteine, procainamide, palifosfamide, cefalotin, decitabine, azacitidine, flucytosine, epigallocatechin gallate, and hydralazine | Module 4 | Epifactor (DNA methylation) |
| SENP3 | Methylphenidate | Module 4 | Epifactor (histone modification erase, histone modification write cofactor) |
| SIRT6 | 7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide | Module 4 | Epifactor (histone modification erase) |
| FOS | Pseudoephedrine and nadroparin | Module 12 | TF |
| RELA | SC-236, betulinic acid, bortezomib, dimethyl fumarate, PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-thiazole, indoprofen | Module 12 | TF |
| STAT1 | Epigallocatechin gallate | Module 12 | TF |
| STAT5A | AZD-1480 | Module 11 | TF |
| SMAD3 | Ellagic acid | Module 10 | TF |